The Abca4/Rdh8-DKO mouse is a dual-gene knockout model obtained by mating Rdh8-KO mice (catalog No.: ^{a href="https://www.cyagen.com/mouseatlas/C001969" style="color: var(--uicolor-main-color);text-decoration: underline;text-underline-offset: 4px;" target="_blank"}C001969^/a) with Abca4-KO mice (catalog No.: ^{a href="https://www.cyagen.com/mouseatlas/C002024" style="color: var(--uicolor-main-color);text-decoration: underline;text-underline-offset: 4px;" target="_blank"}C002024^/a). This model can be used to investigate the pathogenic mechanisms and therapeutic strategies of diseases, including Stargardt disease (STGD) and age‑related macular degeneration (AMD), and facilitates the evaluation of synergistic effects of polygenic therapies.

Stargardt disease (STGD), a hereditary macular dystrophy, is characterized by the presence of yellowish flecks within the retinal pigment epithelium (RPE), ultimately culminating in macular atrophy. Typically manifesting in childhood and adolescence, STGD leads to progressive central vision loss and mild dyschromatopsia. Fundoscopic examination may reveal pale yellow lesions exhibiting a characteristic gold foil-like sheen, accompanied by yellow-white spots surrounding the posterior pole. In advanced stages, atrophy of the RPE, photoreceptors, and choriocapillaris is observed. This bilateral and typically synchronous condition affects both eyes with comparable incidence across sexes, estimated between 1/8,000 and 1/13,000. STGD is predominantly an autosomal recessive disorder, with mutations in the ABCA4 gene accounting for approximately 95% of cases. ABCA4 encodes a retina-specific ABC transporter protein crucial for the clearance of retinal derivatives and toxic metabolites generated during rhodopsin photobleaching. Consequently, ABCA4 mutations result in the accumulation of these cytotoxic substances, triggering apoptosis of both RPE and photoreceptor cells and ultimately driving retinal degeneration. Notably, ABCA4 mutations have been implicated in a spectrum of retinal diseases, including STGD, cone-rod dystrophy (CRD), age-related macular degeneration (AMD), and retinitis pigmentosa (RP), with the specific clinical phenotype correlating with the nature and severity of the ABCA4 mutation. This strain is an Abca4 gene knockout (KO) mouse model. Gene-editing technology was used to delete the protein-coding sequence of the Abca4 gene (the homolog of the human ABCA4 gene) in mice. Previous studies have demonstrated that Abca4 KO mice exhibit delayed dark adaptation following photobleaching and a slow progression of photoreceptor degeneration^[1]. Homozygous Abca4-KO mice are viable and fertile.

The ALMS1 gene encodes the large, multi-domain ALMS1 protein, which localizes primarily to the centrosomes and basal bodies of primary cilia within cells. There, it plays a critical role in microtubule organization, ciliogenesis, endosome recycling (notably of the GLUT4 transporter), and cell cycle regulation ^[1]. Because primary cilia are sensory organelles found on nearly all cell types, the gene is expressed across a wide range of tissues, including the retina, cochlea, pancreatic islets, adipose tissue, renal tubules, and cardiomyocytes. Mutations in ALMS1 lead to Alström syndrome in humans, a rare autosomal recessive ciliopathy marked by progressive multisystem failure, including cone-rod dystrophy (blindness), sensorineural hearing loss, childhood obesity, extreme insulin resistance, type 2 diabetes, and dilated cardiomyopathy ^[2]. Research on mice with Alms1 deficiency has successfully recapitulated the clinical features mentioned above, confirming that the loss of this gene leads to stunted renal cilia, impaired intracellular trafficking in photoreceptors, and metabolic dysfunction that mirrors human disease progression ^[3]. Furthermore, a high-fat diet (HFD) can accelerate the metabolic pathological process in Alms1 KO mice, making them more susceptible to metabolic diseases such as hyperglycemia, hyperinsulinemia, and insulin resistance, while also inducing hepatic inflammation and fibrosis ^[4]. Alms1-del(c.3802-3812) mice are a research model constructed using gene-editing technology to introduce a c.3802_3812 del CAAAAACAGTT mutation into exon 8 of the mouse Alms1 gene. Both homozygous female and male Alms1-del(c.3802-3812) mice were infertile. This model can be utilized for research into the pathological mechanisms and the development of therapeutic interventions for Alström syndrome, as well as metabolic diseases such as obesity, diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

The Cre-P2A cassette was inserted upstream of the ATG start codon.

The TAA stop codon was replaced with the P2A-CreERT2 cassette. CreERT2 recombinase is expressed under the regulatory control of Adgre1 gene elements. This model is a Tamoxifen-inducible Cre mouse, and when crossed with mice containing loxP sites, the offspring mice are expected to undergo sequence recombination between loxP sites mediated by Cre recombinase in macrophages following Tamoxifen induction.

The ADGRL2 gene (Adhesion G Protein-Coupled Receptor L2), also known as latrophilin 2, encodes a member of the adhesion G protein-coupled receptor (aGPCR) family, which are characterized by a long N-terminal domain involved in cell-cell and cell-matrix interactions ^[1]. The encoded protein, ADGRL2, is involved in various physiological processes, including cell adhesion, neuronal development, regulation of exocytosis (e.g., as a low-affinity receptor for alpha-latrotoxin), and maintaining intestinal homeostasis ^[2]. It is expressed in numerous tissues, with notable expression in the central nervous system (neurons, hippocampus), intestinal epithelium, and specifically, its expression is strongly upregulated during keratinocyte differentiation in epidermal tissue ^[3]. Dysregulation or variations in ADGRL2 have been associated with a range of conditions, including neurodegenerative diseases (like Alzheimer's and Parkinson's), inflammatory bowel diseases (Crohn's disease, ulcerative colitis), certain autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis), and even metabolic syndrome and cocaine use disorder. Adgrl2-3xGGGGS-mCherry mice are constructed by replacing the partial exon 1 coding region of the mouse Adgrl2 gene with HA signal peptide - HA tag - Mouse Adgrl2 CDS (without signal peptide) - 3xGGGGS - mCherry - rBG pA cassette using gene editing technology. The Adgrl2-3xGGGGS-mCherry mouse carries a red fluorescent protein (mCherry) expression cassette, making it a precise research model that maintains protein function while offering fluorescence visualization. This model is valuable for several key areas of study. For instance, it can be used for the spatio-temporal dynamic analysis of the Adgrl2 gene expression profile. Researchers can also utilize it for investigating neuronal development and synapse formation mechanisms. Furthermore, it enables live-animal dynamic tracking and real-time imaging observation, providing invaluable insights. Lastly, this model is well-suited for systematic studies of protein interaction networks and downstream signaling pathways.

The adenomatous polyposis coli (APC) gene is a tumor suppressor gene, the protein it encodes plays a key regulatory role in the Wnt/β-catenin signaling pathway ^[1]. The APC protein can antagonize the Wnt signaling pathway, assisting in regulating cell migration, adhesion, transcriptional activation, and apoptosis. More than 10% of human tumors have mutations in the APC gene, and most colorectal cancers have mutations in the APC gene ^[2]. Defects in the APC gene lead to the occurrence of familial adenomatous polyposis (FAP), characterized by hundreds to thousands of adenomatous polyps in the rectum. This is an autosomal dominant precancerous disease, which usually develops into malignant tumors ^[1-2]. Disease-related mutations in the APC gene are highly prevalent in a small region known as the mutation cluster region (MCR), which usually leads to the production of truncated proteins ^[3-4]. In mice, either Apc gene deletion or multiple intestinal neoplasia (Min) mutations that result in the production of truncated APC proteins cause phenotypes similar to human familial adenomatous polyposis (FAP) and/or colorectal tumors ^[5-9]. The Apc KO mouse is a research model constructed by using gene editing technology to knock out the sequence in the mouse Apc gene that contains the mutation cluster region (MCR), and this strain is homozygous lethal. Heterozygous Apc KO mice can spontaneously develop intestinal adenomas and exhibit significant colorectal cancer disease phenotypes in various aspects such as survival, growth, food intake, and intestinal lesions. Therefore, Apc KO mice can be used for familial adenomatous polyposis (FAP) and colorectal cancer and other tumors or tumor-related diseases, as well as the study of the regulatory mechanism of the Wnt/β-catenin signaling pathway.

The ADIPOQ gene-encoded adiponectin is a protein hormone produced exclusively by adipocytes (fat cells). It is transported through the bloodstream to muscle and liver cells. Adiponectin regulates various pathways related to fat storage and metabolism, including the modulation of blood glucose levels, fatty acid breakdown, brown adipocyte differentiation, and negative regulation of gluconeogenesis. By increasing insulin sensitivity and promoting fatty acid breakdown, adiponectin plays a crucial role in regulating glucose and fat metabolism. Additionally, it exhibits direct anti-diabetic, anti-atherosclerotic, and anti-inflammatory activities ^[1-2]. The mutation of the ADIPOQ gene is associated with adiponectin deficiency syndrome. Although the ADIPOQ gene is primarily expressed in adipose tissue, adiponectin is not only present in adipose tissue but is also widely distributed in various organs and tissues, including muscle, liver, intestines, male reproductive glands, and the brain ^[3-4]. The Adipoq-iCre mice are constructed by inserting a codon-improved Cre recombinase (iCre) element into the endogenous Adipoq gene of mice. The expression pattern of iCre recombinase is similar to the endogenous gene. When this strain is crossed with mice containing loxP sites, sequence recombination mediated by the Cre recombinase between loxP sites can occur in the white adipose tissue (WAT) and brown adipose tissue (BAT) of its offspring.

The AGRP gene encodes Agouti-related protein (AgRP), a neuropeptide synthesized by AgRP/NPY neurons predominantly located in the arcuate nucleus of the hypothalamus, as well as in the kidneys and adrenal glands. The expression of AGRP is modulated by various factors, including nutritional status and hormonal signals. Notably, AGRP expression is markedly upregulated during periods of starvation and rapidly downregulated following refeeding. AgRP is exclusively synthesized in the ventromedial part of the arcuate nucleus within neuropeptide Y (NPY)-containing cells, where it is co-expressed with NPY. This neuropeptide plays a pivotal role in enhancing appetite, reducing metabolic rate, and decreasing energy expenditure, making it one of the most potent and enduring appetite stimulators. AgRP exerts its orexigenic effects by antagonizing melanocortin receptor 4 (MC4R), thereby promoting food intake and inhibiting energy expenditure, which is crucial for weight regulation. Mutations in the AGRP gene have been implicated in conditions such as late-onset obesity and anorexia nervosa, underscoring its significant role in energy homeostasis and body weight control. The Agrp-IRES-CreERT2-P2A-tdTomato mouse model was generated by integrating the IRES-CreERT2-P2A-tdTomato gene expression cassette into the endogenous Agrp locus via gene editing technology. Under the control of the mouse endogenous Agrp gene regulatory elements, this mouse expresses tamoxifen-inducible CreERT2 recombinase. Additionally, the cassette includes a red fluorescent protein (tdTomato) for lineage tracing of Agrp-positive cells. In the absence of tamoxifen, CreERT2 recombinase remains cytoplasmic. Upon tamoxifen administration, CreERT2 translocates to the nucleus to mediate recombination. When Agrp-IRES-CreERT2-P2A-tdTomato mice are crossed with mice containing loxP sites, tamoxifen induction can trigger Cre recombinase-mediated sequence recombination between loxP sites in AgRP-positive neurons of the offspring.

The ALPL gene encodes for the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme, a membrane-bound glycoprotein. This enzyme is expressed in a variety of cellular tissues, most notably in the liver, bone, and kidney, as well as in other areas like teeth and mesenchymal stem cells ^[1]. Its primary function is to act as a hydrolase, removing phosphate groups from molecules. This is a critical function for skeletal and dental mineralization, where it hydrolyzes inorganic pyrophosphate (a mineralization inhibitor) into phosphate, which then combines with calcium to form bone ^[2]. Mutations in the ALPL gene lead to hypophosphatasia (HPP), a rare inherited metabolic disease characterized by defective bone and tooth mineralization, rickets, osteomalacia, and in severe cases, seizures and respiratory complications. The severity of HPP varies, ranging from mild forms with dental issues to life-threatening perinatal forms ^[3]. Variations in the ALPL gene may also be associated with other diseases, such as osteoporosis. Research has found a high frequency of homozygous common ALPL gene variants in adult patients with atypical femoral fractures or with biochemical/clinical signs of hypophosphatasia (HPP). This suggests that variations in the ALPL gene may be linked to an increased risk of these fractures ^[4]. Furthermore, the expression and function of the ALPL gene may be relevant to cancer immunotherapy. Studies have shown that an alkaline phosphatase isoform, known as ALPL-1, is highly expressed in osteosarcoma (OS) ^[5]. The Alpl KO mouse is a knockout (KO) model in which the exon 3~4 of the Alpl gene (homologous to the human ALPL gene) has been deleted via gene-editing technology. Preliminary validation data indicate that homozygous Alpl KO mice have a short lifespan, dying within four weeks when given a specialized diet. If they are not provided with this dietary support, no surviving homozygous individuals are obtained. This model can be used to study the pathogenic mechanisms of diseases such as hypophosphatasia (HPP), osteoporosis, and osteosarcoma (OS), and to provide a basis for developing related therapeutic strategies.